See more : Choice International Limited (CHOICEIN.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Timber Pharmaceuticals, Inc. (TMBR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Timber Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Taiwan Cement Corp. (1101.TW) Income Statement Analysis – Financial Results
- Dividend Select 15 Corp. (DVVDF) Income Statement Analysis – Financial Results
- Torunlar Gayrimenkul Yatirim Ortakligi AS (TRGYO.IS) Income Statement Analysis – Financial Results
- Absolute Health and Fitness, Inc. (AHFI) Income Statement Analysis – Financial Results
- Witted Megacorp Oyj (WITTED.HE) Income Statement Analysis – Financial Results
Timber Pharmaceuticals, Inc. (TMBR)
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.18K | 295.74K | 453.81K | 324.65K | 57.00K | 73.00K | 100.00K | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.30M | 6.15M | 1.50M | 3.38M | 83.00K | 250.00K | 516.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -13.22M | -5.85M | -1.05M | -3.06M | -26.00K | -177.00K | -416.00K | -173.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -15,892.35% | -1,979.40% | -230.78% | -941.95% | -45.61% | -242.47% | -416.00% | -270.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.30M | 6.15M | 15.10M | 3.38M | 9.08M | 9.14M | 10.16M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 5.24M | 5.14M | 4.65M | 4.17M | 0.00 | 52.31K | 27.96K | 59.11K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 2.16M | 2.42M | 3.20M | 5.11M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 5.39M | 4.06M | 586.56K | 7.40M | 7.56M | 7.85M | 9.28M | 0.00 | 52.31K | 27.96K | 59.11K |
| Other Expenses | -83.18K | -590.79K | -453.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.24M | 10.95M | 18.71M | 586.72K | 16.48M | 16.70M | 18.01M | 14.99M | 0.00 | 52.31K | 27.96K | 59.11K |
| Cost & Expenses | 19.24M | 10.95M | 18.71M | 3.97M | 16.56M | 16.95M | 18.53M | 15.22M | 0.00 | 52.31K | 27.96K | 59.11K |
| Interest Income | 2.45K | 15.55K | 816.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 0.00 |
| Interest Expense | 228.46K | 15.55K | 4.42M | 0.00 | 28.00K | 364.00K | 163.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 77.45K | 272.88K | 2.43M | 171.86K | 62.00K | 52.00K | 260.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.16M | -10.38M | -17.78M | -45.56K | -17.17M | -16.88M | -17.98M | -15.16M | 0.00 | -52.31K | -27.96K | -59.11K |
| EBITDA Ratio | -23,032.75% | -3,601.23% | -3,917.31% | -14.03% | -30,115.79% | -32,717.81% | -17,981.00% | -24,231.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.24M | -10.65M | -20.21M | -3.64M | -17.23M | -23.94M | -18.24M | -15.59M | 0.00 | -52.31K | -27.96K | -59.11K |
| Operating Income Ratio | -23,125.86% | -3,601.23% | -4,453.82% | -1,122.63% | -30,224.56% | -32,789.04% | -18,241.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -136.45K | -19.17K | 5.13M | -156.00 | -750.00K | 238.00K | -163.00K | -436.00K | 0.00 | 1.00 | 2.00 | 0.00 |
| Income Before Tax | -19.37M | -10.67M | -15.08M | -3.64M | -17.26M | -16.64M | -18.40M | -15.59M | 0.00 | -52.30K | -27.96K | -59.11K |
| Income Before Tax Ratio | -23,289.91% | -3,607.72% | -3,322.93% | -1,122.68% | -30,273.68% | -22,791.78% | -18,404.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 7.60K | -30.24K | 37.84K | -156.00 | 2.00K | -7.66M | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -19.38M | -10.64M | -15.12M | -3.69M | -17.26M | -8.98M | -18.41M | -15.60M | 0.00 | -52.30K | -27.96K | -59.11K |
| Net Income Ratio | -23,299.05% | -3,597.49% | -3,331.27% | -1,136.66% | -30,277.19% | -12,298.63% | -18,406.00% | -24,371.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
| Weighted Avg Shares Out (Dil) | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
Best Penny Stocks to Buy Now? 3 For Your August List
Best Penny Stocks to Buy Under $1? 3 to Watch as April Ends
Timber Pharmaceuticals to Present at H.C. Wainwright BioConnect Conference
Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001
TMBR Stock: Why The Price Plummeted Today
Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
Timber Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Timber Pharmaceuticals Announces Last Patient Last Visit in Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis
Best Penny Stocks to Buy Now? 3 to Watch This Week
7 Hottest Penny Stocks to Pick Up Now
Source: https://incomestatements.info
Category: Stock Reports